Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-based immunotherapy for prostate cancer.

B A Tjoa1, P A Lodge, M L Salgaller

  • 1Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WA, USA.

CA: a Cancer Journal for Clinicians
|February 24, 2001
PubMed
Summary

This study developed a novel prostate cancer vaccine. It utilizes autologous dendritic cells to present prostate antigens, aiming to stimulate T cell responses against cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of Cx43 gap junctions: the gatekeeper and the password.

Science's STKE : signal transduction knowledge environment·2001
Same author

Abbreviated cell cycle progression induced by the serine/threonine protein phosphatase inhibitor okadaic acid at concentrations that promote neoplastic transformation.

Carcinogenesis·2001
Same author

Hydrogen peroxide promotes transformation of rat liver non-neoplastic epithelial cells through activation of epidermal growth factor receptor.

Molecular carcinogenesis·2001
Same author

Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells.

International journal of cancer·2001
Same author

Progress in active-specific immunotherapy of brain malignancies.

Expert opinion on investigational drugs·2000
Same author

Development of dendritic-cell based prostate cancer vaccine.

Immunology letters·2000

Area of Science:

  • Immunology
  • Oncology
  • Cellular Biology

Background:

  • Dendritic cells possess a unique capacity to activate naive T cells, a critical function in initiating adaptive immune responses.
  • Prostate cancer remains a significant health concern, necessitating innovative therapeutic strategies.

Purpose of the Study:

  • To develop and evaluate an autologous dendritic cell-based vaccine for prostate cancer.
  • To investigate the potential of dendritic cells as a delivery vehicle for prostate-specific antigens.

Main Methods:

  • Isolation and preparation of autologous dendritic cells from patients.
  • Loading dendritic cells with relevant prostate cancer antigens.
  • In vivo administration of the dendritic cell vaccine to stimulate T cell responses.

Related Experiment Videos

Main Results:

  • The study demonstrated the feasibility of generating autologous dendritic cell vaccines.
  • Preliminary data suggests the vaccine can present prostate antigens to T cells in vivo.
  • Further studies are needed to confirm the efficacy and safety of this approach.

Conclusions:

  • Autologous dendritic cells represent a promising platform for developing prostate cancer vaccines.
  • This approach holds potential for harnessing the immune system to combat prostate cancer.
  • Future research should focus on clinical trials to assess therapeutic benefits.